{"date":"2025-09-10","count":9,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-4728-2025-09-10-2258-qmmwae","company_id":"4728","company":"雙美","market":"上櫃","industry":"生技醫療","date":"2025-09-10","time":"22:58:56","subject":"公告本公司董事會決議召開114年第一次股東臨時會相關事宜","clause":"第17款","fact_date":"2025-09-10","cite_as":"公開資訊觀測站重大訊息：雙美（4728），2025-09-10 22:58，「公告本公司董事會決議召開114年第一次股東臨時會相關事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1271-2025-09-10-1730-ub84r7","company_id":"1271","company":"晨暉生技","market":"興櫃","industry":"生技醫療","date":"2025-09-10","time":"17:30:45","subject":"公告本公司114年第一次股東臨時會重要決議事項","clause":"第15款","fact_date":"2025-09-10","cite_as":"公開資訊觀測站重大訊息：晨暉生技（1271），2025-09-10 17:30，「公告本公司114年第一次股東臨時會重要決議事項」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6610-2025-09-10-1717-d0mtpb","company_id":"6610","company":"安成生技","market":"興櫃","industry":"生技醫療","date":"2025-09-10","time":"17:17:40","subject":"公告本公司用於治療單純型遺傳性表皮分解性水皰症(EBS)之開發中新藥AC-203，向中國國家藥品監督管理局（NMPA）提出申請進行第二/三期人體臨床試驗。","clause":"第8款","fact_date":"2025-09-10","cite_as":"公開資訊觀測站重大訊息：安成生技（6610），2025-09-10 17:17，「公告本公司用於治療單純型遺傳性表皮分解性水皰症(EBS)之開發中新藥AC-203，向中國國家藥品監督管理局（NMPA）提」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6917-2025-09-10-1606-1vkk8l7","company_id":"6917","company":"竟天","market":"興櫃","industry":"生技醫療","date":"2025-09-10","time":"16:06:15","subject":"本公司114年度現金增資發行新股認股基準日暨相關作業事宜","clause":"第9款","fact_date":"2025-09-10","cite_as":"公開資訊觀測站重大訊息：竟天（6917），2025-09-10 16:06，「本公司114年度現金增資發行新股認股基準日暨相關作業事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4137-2025-09-10-1558-1yh6zjm","company_id":"4137","company":"麗豐-KY","market":"上市","industry":"生技醫療","date":"2025-09-10","time":"15:58:10","subject":"公告本公司受邀參加富邦證券舉辦之法人說明會","clause":"第12款","fact_date":"2025-09-12","cite_as":"公開資訊觀測站重大訊息：麗豐-KY（4137），2025-09-10 15:58，「公告本公司受邀參加富邦證券舉辦之法人說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6469-2025-09-10-1531-1mv4oa8","company_id":"6469","company":"大樹","market":"上櫃","industry":"生技醫療","date":"2025-09-10","time":"15:31:51","subject":"公告本公司國內第一次私募無擔保可轉換公司債到期償還","clause":"第53款","fact_date":"2025-09-10","cite_as":"公開資訊觀測站重大訊息：大樹（6469），2025-09-10 15:31，「公告本公司國內第一次私募無擔保可轉換公司債到期償還」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4105-2025-09-10-1521-107rh2c","company_id":"4105","company":"東洋","market":"上櫃","industry":"生技醫療","date":"2025-09-10","time":"15:21:10","subject":"公告本公司114年8月份自結合併損益","clause":"第53款","fact_date":"2025-09-10","cite_as":"公開資訊觀測站重大訊息：東洋（4105），2025-09-10 15:21，「公告本公司114年8月份自結合併損益」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4732-2025-09-10-1518-codr1t","company_id":"4732","company":"彥臣","market":"興櫃","industry":"生技醫療","date":"2025-09-10","time":"15:18:15","subject":"公告本公司董事會通過子公司御華生醫轉移性葡萄膜黑色素瘤(NBM-BMX-004) 美國二期臨床試驗「委託研究機構」遴選及授權董事長簽署合約","clause":"第44款","fact_date":"2025-09-10","cite_as":"公開資訊觀測站重大訊息：彥臣（4732），2025-09-10 15:18，「公告本公司董事會通過子公司御華生醫轉移性葡萄膜黑色素瘤(NBM-BMX-004) 美國二期臨床試驗「委託研究機構」遴選及」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6919-2025-09-10-1329-1ujq32h","company_id":"6919","company":"康霈*","market":"上市","industry":"生技醫療","date":"2025-09-10","time":"13:29:07","subject":"澄清新聞媒體報導","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：康霈*（6919），2025-09-10 13:29，「澄清新聞媒體報導」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}